Carbamazepine-Induced Stevens-Johnson Syndrome and HLA-B*1502 Screening among First-degree Relatives of Index Patients

• Main Authors: Siqing Ee (Author), Siew-Kiang Tan (Author), Yong-Kwang Tay (Author)
• Format: Book
• Published: Wolters Kluwer Medknow Publications, 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2352-2410; 2352-2429; 10.4103/jdds.jdds_7_19
• Keywords: carbamazepine; drug hypersensitivity; hla-b*1502; stevens-johnson syndrome; toxic epidermal necrolysis; Dermatology; RL1-803
• Source: Journal of Dermatology and Dermatologic Surgery, Vol 23, Iss 2, Pp 90-92 (2019)

Background: Carbamazepine (CBZ) is often implicated in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). CBZ-induced SJS/TEN is strongly associated with the HLA-B*1502 allele in Southeast Asia. Objectives: The objective was to determine the prevalence of HLA-B*1502 allele in patients with CBZ-induced SJS/TEN and in their first-degree relatives. Materials and Methods: Ten cases of CBZ-induced SJS/TEN from a single center were contacted and offered HLA-B*1502 genotyping for themselves and their first-degree relatives. Eight patients and 12 relatives consented for genotyping. Results: HLA-B *1502 was positive in all patients who were tested, of whom 50% of them were Malay and 50% were Chinese. The frequency of the HLA-B*1502 allele in the first-degree relatives was 58%. Conclusion: HLA-B*1502 is common in first-degree relatives of patients with CBZ-induced SJS/TEN.